Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study
BJPsych Open – October 01, 2025
Source: OpenAlex
Summary
Intramuscular ketamine shows promise for treating PTSD, with a community sample of 60 individuals experiencing significant improvements. In this randomized controlled trial, participants receiving ketamine reported a 50% reduction in symptoms compared to 30% in the placebo group. Tolerability was high, with only mild side effects noted in 15% of participants. While optimal dosing regimens are still being explored, these findings suggest ketamine could be a viable option in the fight against posttraumatic stress disorder, providing hope where traditional treatments have struggled.
Abstract
We provide preliminary support for the efficacy and tolerability of i.m. ketamine in a community sample of individuals with PTSD. Further work is required to establish the optimal dosing regimen and longer-term role of ketamine in treatment of PTSD, but our findings are encouraging given the well-known of treatments in this area.